[GIST]

Area of Science:

• Oncology
• Molecular Biology
• Gastroenterology

Background:

• Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the GI tract.
• Recent advances have identified key pathogenetic defects and led to targeted therapies for GIST.
• GIST pathogenesis involves gain-of-function mutations in the c-kit protooncogene, leading to constitutive Kit receptor tyrosine kinase activation and malignant proliferation.

Purpose of the Study:

• To highlight the significance of understanding GIST pathogenetic defects.
• To discuss the development and impact of specific molecular inhibitors for GIST.
• To review the efficacy of imatinib (Gleevec) in treating GIST, particularly metastatic disease.

Main Methods:

• Review of scientific literature on GIST pathogenesis and targeted therapy.
• Analysis of the role of c-kit mutations in GIST development.
• Evaluation of imatinib's mechanism of action and clinical outcomes.

Main Results:

• Imatinib selectively inhibits the activated c-Kit tyrosine kinase.
• The efficacy of imatinib demonstrates that targeted inhibitors can overcome genetic defects driving cancer.
• Imatinib has revolutionized the treatment of metastatic GIST.

Conclusions:

• Targeted therapy based on specific molecular defects is a paradigm shift in cancer treatment.
• Further development of molecularly targeted agents for GIST is ongoing.
• Understanding the molecular basis of GIST has paved the way for effective therapeutic strategies.